Incidence and risk factors for HIV-tuberculosis coinfection in the Cologne-Bonn region: a retrospective cohort study.
Antiretroviral therapy
Germany
HIV
Immigrants
TB low-burden country
Tuberculosis
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
16 Mar 2024
16 Mar 2024
Historique:
received:
31
12
2023
accepted:
13
02
2024
medline:
16
3
2024
pubmed:
16
3
2024
entrez:
16
3
2024
Statut:
aheadofprint
Résumé
The risk of developing active tuberculosis (TB) is considerably increased in people living with HIV/AIDS (PLWH). However, incidence of HIV/TB coinfection is difficult to assess as surveillance data are lacking in many countries. Here, we aimed to perform a quantitative analysis of HIV/TB coinfections within the Cologne/Bonn HIV cohort and to determine risk factors for active TB. We systematically evaluated data of patients with HIV/TB coinfection between 2006 and 2017. In this retrospective analysis, we compared HIV/TB-coinfected patients with a cohort of HIV-positive patients. The incidence density rate (IDR) was calculated for active TB cases at different time points. During 2006-2017, 60 out of 4673 PLWH were diagnosed with active TB. Overall IDR was 0.181 cases/100 patient-years and ranged from 0.266 in 2006-2009 to 0.133 in 2014-2017. Patients originating from Sub-Saharan Africa had a significantly (p < 0.001) higher IDR (0.694/100 patient-years of observation, 95% CI [0.435-1.050]) in comparison to patients of German origin (0.053/100 patient-years of observation, 95% CI [0.028-0.091]). In terms of TB-free survival, individuals originating from countries with a TB incidence higher than 10/100,000 exhibited a markedly reduced TB-free survival compared to those originating from regions with lower incidence (p < 0.001). In 22 patients, TB and HIV infection were diagnosed simultaneously. Overall, we observed a decline in the incidence density rate (IDR) of HIV/TB coinfections between 2006 and 2017. Patients originating from regions with high incidence bear a higher risk of falling ill with active TB. For PLWH born in Germany, the observed risk of active TB appears to be lower compared to other groups within the cohort. These findings should be considered when developing TB containment and screening strategies for PLWH in low-incidence countries.
Identifiants
pubmed: 38492196
doi: 10.1007/s15010-024-02215-y
pii: 10.1007/s15010-024-02215-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsches Zentrum für Infektionsforschung
ID : TI 07.001_SUAREZ_00
Organisme : Deutsches Zentrum für Infektionsforschung
ID : TTU 02.806
Organisme : German Federal Ministry of Education and Research (BMBF)
ID : 01KI1017
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 1403
Organisme : Innovative Medicines Initiative 2 Joint Undertaking
ID : No. 853989 (ERA4TB)
Informations de copyright
© 2024. The Author(s).
Références
ECDC/WHO. Tuberculosis surveillance and monitoring report in Europe 2019. 2019.
ECDC/WHO. Tuberculosis surveillance and monitoring in Europe 2022. 2022.
WHO. Global tuberculosis report 2023. 2023.
ECDC/WHO. Tuberculosis surveillance and monitoring in Europe 2023. 2023.
UNAIDS. Fact sheet—world tuberculosis day 2022. 2022.
Getahun H, et al. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis. 2010;50:S201–7.
doi: 10.1086/651492
pubmed: 20397949
WHO. Global tuberculosis report 2019. 2019.
Tiberi S, et al. The cursed duet today: tuberculosis and HIV-coinfection. Presse Med. 2017;46:e23–39.
doi: 10.1016/j.lpm.2017.01.017
pubmed: 28256380
Schaberg T, et al. Tuberculosis guideline for adults—guideline for diagnosis and treatment of tuberculosis including LTBI testing and treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP). Pneumologie. 2017;71:325–97.
pubmed: 28651293
WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. 2017.
Schaberg T, et al. Tuberculosis in adulthood—the Sk2-guideline of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the diagnosis and treatment of adult tuberculosis patients. Pneumologie. 2022;76:727–819.
pubmed: 36384164
WHO. Global tuberculosis report 2022. 2022.
Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland 2022. 2023.
Bundesamt S. Migration 2021: 329 000 Personen mehr zu- als abgewandert. 2022.
Rockstroh JK. The Cologne–Bonn cohort: lessons learned. Infection. 2015;43:135–9.
doi: 10.1007/s15010-015-0745-2
pubmed: 25708018
Ehren K, et al. Causes of death in HIV-infected patients from the Cologne–Bonn cohort. Infection. 2014;42:135–40.
doi: 10.1007/s15010-013-0535-7
pubmed: 24081925
Karo B, et al. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy. BMC Infect Dis. 2017;17:517.
doi: 10.1186/s12879-017-2627-y
pubmed: 28743248
pmcid: 5526303
ECDC/WHO. Tuberculosis surveillance and monitoring in Europe 2017. 2017.
Aldridge RW, et al. Tuberculosis in migrants moving from high-incidence to low-incidence countries: a population-based cohort study of 519 955 migrants screened before entry to England, Wales, and Northern Ireland. Lancet. 2016;388:2510–8.
doi: 10.1016/S0140-6736(16)31008-X
pubmed: 27742165
pmcid: 5121129
CDC. Principles of epidemiology/lesson 3: measures of risk. 2012.
Karo B, et al. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis. 2014;14:148.
doi: 10.1186/1471-2334-14-148
pubmed: 24646042
pmcid: 3994660
Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2015. 2016
Sonnenberg P, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005;191:150–8.
doi: 10.1086/426827
pubmed: 15609223
Bruchfeld J, Correia-Neves M, Kallenius G. Tuberculosis and HIV Coinfection. Cold Spring Harb Perspect Med. 2015;5: a017871.
doi: 10.1101/cshperspect.a017871
pubmed: 25722472
pmcid: 4484961
Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection. Nat Rev Microbiol. 2018;16:80–90.
doi: 10.1038/nrmicro.2017.128
pubmed: 29109555
Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev. 2011;24:351–76.
doi: 10.1128/CMR.00042-10
pubmed: 21482729
pmcid: 3122491
Seneadza NAH, et al. Assessing risk factors for latent and active tuberculosis among persons living with HIV in Florida: a comparison of self-reports and medical records. PLoS ONE. 2022;17:e0271917.
doi: 10.1371/journal.pone.0271917
pubmed: 35925972
pmcid: 9352085
Adhikari N, et al. Prevalence and associated risk factors for tuberculosis among people living with HIV in Nepal. PLoS ONE. 2022;17: e0262720.
doi: 10.1371/journal.pone.0262720
pubmed: 35089953
pmcid: 8797228
Aung ZZ, et al. Survival rate and mortality risk factors among TB-HIV co-infected patients at an HIV-specialist hospital in Myanmar: a 12-year retrospective follow-up study. Int J Infect Dis. 2019;80:10–5.
doi: 10.1016/j.ijid.2018.12.008
pubmed: 30572021
Shah GH, et al. Risk factors for TB/HIV coinfection and consequences for patient outcomes: evidence from 241 clinics in the Democratic Republic of Congo. Int J Environ Res Public Health. 2021;18:5165.
doi: 10.3390/ijerph18105165
pubmed: 34068099
pmcid: 8152772
Dinmohamed AG, et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020;21:750–1.
doi: 10.1016/S1470-2045(20)30265-5
pubmed: 32359403
pmcid: 7252180
Del Cura-Gonzalez I, et al. What have we missed because of COVID-19? Missed diagnoses and delayed follow-ups. SESPAS Report 2022. Gac Sanit. 2022;36:S36–43.
pubmed: 35781146
pmcid: 9244613
Visca D, et al. Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects. Pulmonology. 2021;27:151–65.
doi: 10.1016/j.pulmoe.2020.12.012
pubmed: 33547029
pmcid: 7825946
ECDC/WHO. HIV/AIDS surveillance in Europe 2021 (2020 data). 2021.